Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Southern Italy's national cancer institute, a global leader in melanoma immunotherapy trials under Paolo Ascierto.
The Fondazione Pascale is the IRCCS national cancer institute for southern Italy and one of the largest cancer hospitals in the country. Paolo Ascierto's melanoma, immunotherapy and innovative therapies unit has been a leading investigator in the CheckMate and RELATIVITY trials that established checkpoint blockade and the nivolumab-relatlimab combination in melanoma, and the institute hosts the Melanoma Bridge and Immunotherapy Bridge meetings. Nicola Normanno's molecular biology group is a reference for liquid biopsy and predictive biomarkers in lung and colorectal cancer. Clinical programmes span thoracic, gastrointestinal, breast, urological and head and neck oncology, radiotherapy and haematology, with a phase 1 unit and a Campania-wide oncology network role.
- Melanoma immunotherapy trials
- Predictive biomarkers and liquid biopsy
- Thoracic oncology
- Campania oncology network
Pages like this
not linked directly; found by shared links- Key paperCheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later
Shares CheckMate 067, Relatlimab + nivolumab, LAG-3, CTLA-4.
- Key paperRELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma
Shares CheckMate 067, Relatlimab + nivolumab, LAG-3, Bristol Myers Squibb.
- InstitutionDartmouth Cancer Center
Shares CTLA-4, Ipilimumab, Bristol Myers Squibb, Nivolumab.
- TrialRELATIVITY-047
Shares CheckMate 067, Relatlimab + nivolumab, LAG-3, Nivolumab.
- Key paperCheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma
Shares CheckMate 067, Relatlimab + nivolumab, CTLA-4, Ipilimumab.
- TrialCheckMate 9DW
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1.
- PersonF. Stephen Hodi
Shares CheckMate 067, CTLA-4, Ipilimumab, Nivolumab.
- TrialKEYNOTE-006
Shares CTLA-4, Ipilimumab, PD-1, Melanoma.